{"log_id": 6351229251080901339, "direction": 0, "words_result_num": 25, "words_result": [{"probability": {"variance": 9e-05, "average": 0.996144, "min": 0.949475}, "location": {"width": 802, "top": 224, "height": 46, "left": 223}, "words": "在开始阿昔替尼治疗前应监测尿蛋白,在阿昔替尼治疗期间应定期监测尿蛋白。出"}, {"probability": {"variance": 0.000103, "average": 0.994749, "min": 0.957052}, "location": {"width": 680, "top": 281, "height": 45, "left": 177}, "words": "现中度至重度蛋白尿的患者应降低阿昔替尼剂量或暂停使用阿昔替尼"}, {"probability": {"variance": 9e-05, "average": 0.985461, "min": 0.971289}, "location": {"width": 97, "top": 351, "height": 28, "left": 178}, "words": "肝酶升高"}, {"probability": {"variance": 5.7e-05, "average": 0.996896, "min": 0.95791}, "location": {"width": 802, "top": 388, "height": 46, "left": 224}, "words": "在接受阿昔替尼治疗的RCC患者对照临床研究中,两个治疗组中分别有22%的患"}, {"probability": {"variance": 0.00095, "average": 0.99073, "min": 0.841796}, "location": {"width": 843, "top": 443, "height": 47, "left": 179}, "words": "者发生过所有级别的ALT升高。阿昔替尼治疗组中<1%的患者和索拉非尼治疗组中2%"}, {"probability": {"variance": 0.00597, "average": 0.9847, "min": 0.497341}, "location": {"width": 845, "top": 498, "height": 46, "left": 182}, "words": "的患者发生3/4级ALT升高事件。最常见的肝脏相关不良反应包括ALT、AST和血胆"}, {"probability": {"variance": 0.002604, "average": 0.982758, "min": 0.715756}, "location": {"width": 846, "top": 552, "height": 47, "left": 181}, "words": "红素升高(见【不良反应】)。未观察到ALT(>3倍正常上限[ULN])和胆红素(>2倍"}, {"probability": {"variance": 0.000404, "average": 0.985812, "min": 0.940425}, "location": {"width": 161, "top": 622, "height": 27, "left": 182}, "words": "ULN)同时升高"}, {"probability": {"variance": 0.004952, "average": 0.979228, "min": 0.582009}, "location": {"width": 802, "top": 660, "height": 46, "left": 228}, "words": "在一项临床剂量探索研究中,ALT(12倍ULN)和胆红素(2.3倍ULN)同时升"}, {"probability": {"variance": 2.1e-05, "average": 0.997976, "min": 0.978114}, "location": {"width": 846, "top": 715, "height": 48, "left": 182}, "words": "高被认为是与药物相关的肝毒性,在接受阿昔替尼起始剂量20mg每日两次(推荐起始"}, {"probability": {"variance": 2.2e-05, "average": 0.997526, "min": 0.979702}, "location": {"width": 409, "top": 778, "height": 39, "left": 184}, "words": "剂量的4倍)的1例患者中观察到该毒性"}, {"probability": {"variance": 0, "average": 0.513813, "min": 0.513813}, "location": {"width": 51, "top": 778, "height": 43, "left": 973}, "words": " Ay"}, {"probability": {"variance": 1.9e-05, "average": 0.99815, "min": 0.979625}, "location": {"width": 800, "top": 824, "height": 46, "left": 230}, "words": "在开始阿昔替尼治疗前应监测ALT、AST及胆红素,并在整个治疗期间定期监测"}, {"probability": {"variance": 0, "average": 0.999715, "min": 0.999655}, "location": {"width": 93, "top": 895, "height": 27, "left": 185}, "words": "这些参数"}, {"probability": {"variance": 0.003842, "average": 0.942715, "min": 0.855222}, "location": {"width": 70, "top": 950, "height": 27, "left": 187}, "words": "肝损害"}, {"probability": {"variance": 0.000908, "average": 0.990952, "min": 0.82403}, "location": {"width": 801, "top": 986, "height": 48, "left": 233}, "words": "在阿昔替尼临床研究中,中度肝损害( Child- Pugh B级)受试者中阿昔替尼的全身"}, {"probability": {"variance": 0.004121, "average": 0.987278, "min": 0.60803}, "location": {"width": 849, "top": 1042, "height": 47, "left": 186}, "words": "暴露量大约比正常肝功能受试者高2倍。中度肝损害患者( Child- Pugh B级)接受阿昔"}, {"probability": {"variance": 0.002899, "average": 0.986933, "min": 0.677588}, "location": {"width": 847, "top": 1096, "height": 48, "left": 188}, "words": "替尼治疗时,建议降低剂量。尚未在重度肝损害( Child- Pugh C级)的患者中研究(见"}, {"probability": {"variance": 2.7e-05, "average": 0.996306, "min": 0.97854}, "location": {"width": 650, "top": 1154, "height": 44, "left": 195}, "words": "【用法用量】和【药代动力学】),不应在这类患者中使用阿昔替尼"}, {"probability": {"variance": 0.009539, "average": 0.900101, "min": 0.802431}, "location": {"width": 45, "top": 1226, "height": 25, "left": 191}, "words": "妊娠"}, {"probability": {"variance": 0.000368, "average": 0.994637, "min": 0.885269}, "location": {"width": 804, "top": 1261, "height": 47, "left": 235}, "words": "根据阿昔替尼的作用机制,孕妇服用阿昔替尼可能对胎儿造成致命伤害。目前尚未"}, {"probability": {"variance": 1.5e-05, "average": 0.998572, "min": 0.978215}, "location": {"width": 848, "top": 1315, "height": 53, "left": 192}, "words": "在妊娠妇女中进行阿昔替尼的充分和对照研究。在小鼠发育毒性研究中,当母体暴露量"}, {"probability": {"variance": 0.000418, "average": 0.992683, "min": 0.89046}, "location": {"width": 838, "top": 1371, "height": 53, "left": 192}, "words": "低于临床推荐剂量的人体暴露量时,观察到阿昔替尼有致畸性、胚胎毒性和胎儿毒性"}, {"probability": {"variance": 1.1e-05, "average": 0.996385, "min": 0.989237}, "location": {"width": 141, "top": 1583, "height": 24, "left": 552}, "words": "第12页,共27页"}, {"probability": {"variance": 0.036717, "average": 0.918828, "min": 0.412228}, "location": {"width": 65, "top": 1617, "height": 18, "left": 282}, "words": "2015042"}], "language": 3}